LCZ696, a new combination of angiotensin and enkephalinase inhibitor, could reduce the protein expression levels of VEGF-C, VEGFR3, and LYVE-1 in heart tissue of mice and improve the transport load of lymphatic vessels to macrophages, thus inhibiting the remodeling of lymphatic system in a hypertrophic cardiomyopathy model (112). The gene discussed is VEGFC; the disease is hypertrophic cardiomyopathy.